Less DNA & Less Reagent
Lipidomia was established in 2020 as a biotech company focusing on the development of lipid/polymer-based liponanoparticles for gene delivery and protein delivery in vivo based on life science technology. By adding “-ia” to “lipidome” which means a whole cellular lipid network, Lipidomia has the meaning of “lipid world” and represents a company with lipid-based technology.
Our core business is to provide the biochemical reagents and the research services required in life science research. We are currently developing DNA/RNA gene delivery system and cell-penetrating proteins in a basic biological research area and will apply these techniques in the areas of diagnosis and therapeutics. We aim to grow into an internationally competitive biotech company in the gene and protein delivery system.
ADD. 13120 / 1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Korea
Biotechnology requires a time-consuming research and expertise, and contributes to improve the quality of life via the efforts to maintain a good health. To fulfill this objective, a line of biological and medical researches is actively in progress and those necessitate the reagents and equipments for the biochemical analysis.
Lipidomia was founded in 2020 as a start-up from a university laboratory, and is conducting a research on lipid/polymer-based gene delivery systems and cell-penetrating proteins. Our aim is to develop the analytical reagents for biochemical and molecular biological analyses. In particular, the delivery technology of the genes and proteins is not only required for the research of basic life science, but essential for the development of cell therapy for the treatment of the patients inflicted with infectious and genetic diseases. We have a long-history of research experience in lipidology and lipid-related diseases, and have been recognized as the experts in lipid research.
Currently, Lipidomia aims to grow into a research-oriented company with global competitiveness via the development of biological materials for bio research based on the distinguished expertise in the related fields. We will do our best to contribute to the development of novel methods for early diagnosis of diseases and cell therapy along with the fundamental support for basic life science research.
CEO of Lipidomia Co., Ltd.